Trump Administration Sues Gilead Over Truvada PReP for HIV Prevention
The Trump administration, via the Department of Health and Human Services (HHS), filed a lawsuit against Gilead Sciences over Truvada for HIV prevention.
Featured Posts
First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Abbott Announces Discovery of New Strain of HIV
A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.
Oooooh, That’s Scary! Welcome to the Dark Side of Biopharma
For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
Gilead posts third-quarter 2019 net loss, sales in line with Street estimates
Gilead Sciences Inc. reported third-quarter results largely in line with Wall Street estimates, led by higher sales of the company’s HIV drugs, but deal-related costs led to a net loss.
Injectable Hormone Found to Reverse Liver Disease in HIV Patients
Researchers at the National Institutes of Health (NIH) and Massachusetts General Hospital (MGH) in Boston published research that found an injectable hormone called tesamorelin decreases liver fat and prevented liver fibrosis in HIV patients affected by non-alcoholic fatty liver disease.
New Research Suggests a Cure for HIV Could be on the Horizon
Researchers at the University of California, San Diego (UCSD) School of Medicine have identified a key switch that has the potential to eliminate dormant HIV reservoirs.
W2O Joins Forces with International AIDS Society to Raise Awareness of AIDS 2020
W2O – the leading independent analytics-driven, digital-first marketing communications firm to the healthcare sector – will provide regional communications support to the International AIDS Society (IAS) for AIDS 2020, the 23rd International AIDS Conference.
Merck’s Pifeltro and Delstrigo Receive FDA Approval for Virologically Suppressed Adults with HIV-1
The U.S. FDA approved Merck’s supplemental New Drug Applications for Pifeltro (in combination with other antiretroviral agents) and Delstrigo (as a complete regimen) that expand their indications to include adult patients with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to Pifeltro or the individual components of Delstrigo.
GSK’s long acting HIV injection gets boost from study
GlaxoSmithKline’s experimental HIV injection is as effective when given every other month as monthly, according to a study
FDA panel backs Gilead’s HIV prevention drug Descovy, except in women
An FDA advisory panel voted in favor of Gilead’s combination drug to reduce the risk of sexually acquired HIV infection in men.
Ad Right Top
Most Commented
Sorry. No data so far.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!